Tariq Hassan is a freelance writer specializing in men's health, hormonal health, and direct-to-consumer healthcare. He has spent the last four years reviewing TRT clinics, testosterone protocols, and the fine print that most people skip. Tariq got into this space after noticing how confusing and overhyped most of the information online was. Outside of writing, he lifts weights with religious consistency, follows F1 more than he probably should, and makes an extremely good lamb stew.
Regulatory noticeRegulatory note (verified August 22, 2026): A May 2026 review of maximustribe.com led the FDA to issue Maximus Health, Inc. warning letter MARCS-CMS 730095 on June 8, 2026. The language quoted here concerns effect and sourcing rather than ingredient comparison: "Clinically studied ingredients," "Clinically studied to help patients...," and "Proven to lose weight effectively," alongside a statement that the compounded products come from "FDA approved pharmacies." On that last point the agency was explicit that no FDA-approved or FDA-licensed designation exists for compounding pharmacies or outsourcing facilities, so describing one that way is misleading. Both findings were cited as misbranding under FD&C Act 502(a) and 502(bb). Nothing in FDA’s index records a close-out, so we log the matter as open. Read the FDA letter
Regulatory noticeRegulatory note (verified August 22, 2026): On September 9, 2025 the FDA sent Hims & Hers Health, Inc. a warning letter covering the Hims brand, MARCS-CMS 716567, drawn from a review of hims.com the previous month. Two lines about compounded semaglutide are quoted in it: "Same active ingredient as Ozempic and Wegovy" and "Clinically proven ingredients." Compounded drug products are not FDA-approved, and the agency said phrasing of this sort suggests otherwise, which is what makes the products misbranded under FD&C Act sections 502(a) and 502(bb). A companion letter went to the same company that day for its Hers brand. No close-out letter appears in FDA’s index; treat this as open. Read the FDA letter